Trial reportPediatric blood & cancer2026
Cognitive Functioning in Vorinostat-Treated Pediatric and Young Adult Patients Over the First 180 Days After Hematopoietic Stem Cell Transplant.
Trial report in Pediatric blood & cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03842696 (A Phase 1/2 Multi-Center Trial of Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1/2 Multi-Center Trial of Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeCognitive and psychological difficulties could negatively interfere with treatment adherence and quality of life before and after hematopoietic stem cell transplant (HSCT). Methods to mitigate these changes may have positive effects on treatment success. Prior work has shown that histone deacetylases (HDAC) inhibitors such as vorinostat show promise in reducing the incidence of graft-versus-host disease (GVHD) in allogenic transplant recipients and may mitigate some of the cognitive changes seen following transplant in adults. The current work presents a planned secondary analysis of a phase I/II trial of vorinostat for GVHD prophylaxis (NCT03842696) to establish a cognitive and psychological safety profile for use of this emerging therapeutic in a sample of children, adolescents, and young adults.
methodsThirty-two allogeneic transplant recipients (median age = 19) were evaluated with cognitive and health-related quality-of-life (HRQL) measures prior to transplant and at 100 days and 180 days after transplant (N = 25 (cognitive) and 25 (HRQL) at final endpoint). Kolmogorov-Smirnov tests and linear mixed effects modeling were used to compare cognitive performances and HRQL to normative levels and to examine changes over time.
resultsNotable cognitive impairments prior to transplant remained relatively stable throughout the first 180 days post-transplant, with no new neurocognitive safety signal over 180 days. Anxiety was apparent at baseline, but behavioral symptoms remained relatively well managed.
conclusionResults highlight cognitive impairments present prior to transplant and support prior findings in an adult population, suggesting that vorinostat does not result in additional cognitive or psychological deficits following transplant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.